The company has not filed an annual or quarterly report since its Q3 FY2021 10-Q, filed Nov 12, 2021. Its latest SEC filing is a 15-12B from Nov 29, 2021.
10-Q for Q3 FY2021, filed Nov 12, 2021
The sections below describe the company as of the FY2020 annual report.
Develops experimental cancer drugs designed to help immune cells detect and attack tumors, for patients with blood cancers and solid tumors.
10-K for FY2020, filed Mar 18, 2021
Customers are licensees that obtain rights to Trillium product candidates under licensing agreements.
10-K for FY2020, filed Mar 18, 2021The Company enters into licensing agreements which are within the scope of ASC 606, Revenue from Contracts with Customers (“ASC 606”)…View ↗
10-Q for Q3 FY2021, filed Nov 12, 2021
−$19.3MView ↗
8-K, filed Nov 17, 2021
In connection with the Arrangement, at 12:01 a.m. (Pacific Standard Time) (the “Effective Time”) on November 17, 2021 (the “Closing Date”)…View ↗
8-K, filed Aug 23, 2021
On August 20, 2021, Trillium Therapeutics Inc., a corporation existing under the laws of the Province of British Columbia (“Trillium”)…View ↗
Competes with Forty Seven and Gilead Sciences
10-K for FY2020, filed Mar 18, 2021There are a number of other CD47-SIRPα blocking agents in development, including other SIRPαFc fusion proteins, CD47-specific antibodies…View ↗
Loading...
